Hyogo, Japan – April 1, 2026 – JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced the redesign of its corporate website.
The website features a fully revised structure and visual design intended to make JCR’s business activities and corporate perspective easier for stakeholders to understand. It has also been optimized for a wide range of devices, including smartphones and tablets. Building on the visual identity introduced with the launch of JCR’s global website in June 2025, both the Japanese and English versions of the Japan website have been refreshed. The design also reflects JCR’s corporate slogan, “Life is Rare,” to communicate its values and direction consistently to stakeholders in Japan and around the world.
Key features of the redesigned website:
A clearer view of JCR’s business
Reorganizing the site to make the role, features, and strengths of each business easier to understand.
Clearer communication of JCR’s message
Presenting JCR’s corporate philosophy, business approach, direction, and value more clearly.
Easier access to information
Redesigning navigation to help visitors access the information they need more smoothly.
Optimized for a better viewing experience
Providing comfortable viewing across devices, including smartphones and tablets.
JCR remains committed to appropriate disclosure and to further enhancing its corporate value.
Website Links:
Japanese website: https://www.jcrpharm.co.jp/
English website: https://www.jcrpharm.co.jp/en/
Global website: https://www.jcrpharm.com/
About JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world’s most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients’ lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including partners, patients and employees. We strive to expand the possibilities for patients while accelerating medical advancement at a global level.
Contact
Investors & Media:
JCR Pharmaceuticals Co., Ltd.
Corporate Communications
ir-info@jp.jcrpharm.com